CC
SRPT icon

Casdin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Casdin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,000
Closed -$3.45M – 43
2023
Q1 		$3.45M Buy
+25,000
New +$3.24M 0.28% 36

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Casdin Capital's SRPT Position: Q2 2026 in Review

Casdin Capital opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 470,000 shares worth $8.45M. The stake represents 0.42% of the portfolio and ranks #29 among its holdings. This is a return to the name: Casdin Capital previously reported a position in SRPT as recently as Q2 2025.

Casdin Capital first reported a position in SRPT in Q3 2018 and has held it in 29 quarters since. The position peaked at $170M in Q4 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Casdin Capital held 470,000 shares of Sarepta Therapeutics worth $8.45M as of Q2 2026.
  • Sarepta Therapeutics was a new Casdin Capital position in Q2 2026.
  • Sarepta Therapeutics made up 0.42% of Casdin Capital's portfolio in Q2 2026, its #29 holding.
  • Casdin Capital first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Casdin Capital's Sarepta Therapeutics position peaked at $170M in Q4 2022.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.